Thursday 16 October, 2025
Introduction: Natalizumab is highly effective in treating relapsing-remitting multiple sclerosis. However, the standard intravenous treatment interval of 4 weeks may…
Read morePoster: Clinical Applications
External evaluation of pharmacometric models of moxifloxacin for Bayesian forecasting in the treatment of tuberculosis
Thursday 16 October, 2025
Objectives: Personalization of drug therapy can be realized using therapeutic drug monitoring (TDM). A personalized dose for an individual can be…
Read moreA Pharmacometric approach for opioid use disorder in Puerto Rico: A research agenda to individualize buprenorphine pharmacotherapy.
Thursday 16 October, 2025
Objectives: The objective of this poster is to present our strategy for transforming the current standard of care for opioid use…
Read moreA Bayesian (P)K-TTE model to support early dose escalation decisions in phase 1 Oncology studies
Thursday 16 October, 2025
Introduction The design of phase I trials in oncology follows mainly a dose-escalation (DE) design monitoring dose limiting toxicity (DLT)…
Read moreA revised population pharmacokinetic model for recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin
Thursday 16 October, 2025
Introduction: In haemophilia, the vast majority of the existing population pharmacokinetic (PK) models use weight (WT) to normalize the PK…
Read moreBayesian forecasting of recombinant factor IX-Fc fusion protein concentrate dosing in haemophilia B patients: Comparison of the performance of two population pharmacokinetic models
Thursday 16 October, 2025
Introduction: Recombinant factor IX Fc fusion protein (rFIX-Fc) is an extended half-life (EHL)-clotting factor concentrate administered to haemophilia B patients….
Read morePopulation pharmacokinetics of cytarabine and its metabolite in patients with acute myeloid leukemia: effect of cytidine deaminase activity.
Thursday 16 October, 2025
Objectives: Cytarabine-based chemotherapy represents a cornerstone in the current leukemia’s therapeutic arsenal, yet the outcomes remain unsatisfactory due to toxicity and…
Read moreOPTIMIZATION OF THE DOSAGE REGIMEN OF LONG-ACTING INJECTABLE ARIPIPRAZOLE THROUGH MONTE CARLO SIMULATIONS
Thursday 16 October, 2025
Introduction/Objectives: Aripiprazole is an atypical antipsychotic widely used in the treatment of schizophrenia, bipolar disorder, and major depressive disorder with…
Read moreModel-derived PK target profile of ustekinumab therapeutic thresholds in inflammatory bowel diseases to guide precision dosing
Thursday 16 October, 2025
Objectives: Inflammatory bowel diseases (IBD) are a group of chronic immune-mediated diseases affecting the gastrointestinal tract, causing debilitating symptoms such…
Read moreSteps Toward Model-Informed Precision Dosing of PEG-Asparaginase in Children and Young Adults
Thursday 16 October, 2025
Introduction: Polyethylene glycol-conjugated asparaginase (PEG-ASNase) is integral in the treatment for acute lymphoblastic leukemia (ALL) in children and young adults…
Read more